By combining data science, therapeutics and therapy-guiding tests, we first understand each patients’ underlying biology and likely response to treatment, and then develop and commercialize targeted therapeutic solutions intended to meet their needs. By rewriting the molecule-first drug development model, we aim to deliver precision therapies that have the potential to improve outcomes for patients with immune-driven illnesses.

One-size-fits-all treatments don’t work for many patients. At Endpoint Health, we’re patient-first, not molecule-first.

Our vision is a world in which all patients get the best treatment possible for their unique biology and disease.